Imunon Q3 EPS Boosted by Brookline Capital Markets

Imunon, Inc. (NASDAQ:IMNN) – Equities research analysts at Brookline Capital Markets increased their Q3 2026 earnings per share (EPS) estimates for shares of Imunon in a report issued on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($0.71) per share for the quarter, up from their previous forecast of ($0.74). The consensus estimate for Imunon’s current full-year earnings is ($3.46) per share. Brookline Capital Markets also issued estimates for Imunon’s Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.89) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.76) EPS, Q3 2027 earnings at ($0.76) EPS, Q4 2027 earnings at ($0.73) EPS and FY2027 earnings at ($3.03) EPS.

Imunon (NASDAQ:IMNN) last released its earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research note on Friday, July 17th. Maxim Group set a $10.00 price objective on Imunon and gave the company a “buy” rating in a report on Friday, April 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Imunon Price Performance

IMNN stock opened at $1.58 on Friday. The company has a 50 day simple moving average of $1.79 and a 200 day simple moving average of $2.53. The stock has a market cap of $8.86 million, a price-to-earnings ratio of -0.41 and a beta of 1.97. Imunon has a 1 year low of $1.47 and a 1 year high of $6.99.

Institutional Investors Weigh In On Imunon

An institutional investor recently bought a new stake in Imunon stock. Armistice Capital LLC acquired a new position in shares of Imunon, Inc. (NASDAQ:IMNN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.